Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

The objective of this review is to provide an update on the fluorine-containing drugs approved by U.S. Food and Drug Administration in the span of past five years (2018–2022). The agency accepted a total of fifty-eight fluorinated entities to diagnose, mitigate and treat a plethora of diseases. Among them, thirty drugs are for therapy of various types of cancers, twelve for infectious diseases, eleven for CNS disorders, and six for some other diseases. These are categorized and briefly discussed based on their therapeutic areas. In addition, this review gives a glimpse about their trade name, date of approval, active ingredients, company developers, indications, and drug mechanisms. We anticipate that this review may inspire the drug discovery and medicinal chemistry community in both industrial and academic settings to explore the fluorinated molecules leading to the discovery of new drugs in the near future.

Original languageEnglish (US)
Article number115476
JournalEuropean journal of medicinal chemistry
Volume256
DOIs
StatePublished - Aug 5 2023

Keywords

  • CNS disorders
  • Cancer
  • Diagnosis
  • Drug development
  • Drug discovery
  • FDA-approved drugs
  • Fluorinated drugs
  • Fluorine
  • Infectious diseases
  • PET imaging
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)'. Together they form a unique fingerprint.

Cite this